Jonathan Lewis, MD, PhD
Surgical Oncologist | Surgical Oncology
Syncromune Fort Lauderdale FL, 33301About
Dr. Jonathan Lewis is a surgical oncologist practicing in Fort Lauderdale, FL. Dr. Lewis specializes in the diagnosis, treatment and prevention of complex surgical oncologic diseases and immmunologic oncologic and experimental oncology.
Education and Training
Yale PhD 1994
Witwatersrand University MD 0
Board Certification
American Board of Surgery
Provider Details
Jonathan Lewis, MD, PhD's Expert Contributions
What is this
Hi there. Please go and see a fully vetted medical professional as soon as you can. You must make sure not cancer, even though may not be. This is something to be seen and dealt with as soon as possible. Jon READ MORE
Faculty Titles & Positions
- Chief Strategy Officer Syncromune -
- Executive Chairman, CEO, and Chief Medical Officer Ziopharm Oncology -
- Chairman and Chief Medical Officer Antigenics, Inc -
- attending surgeon Department of Surgery -
- attending physician Clinical Immunology Service, Division of Hematologic Oncology -
- Professor Weill Medical College of Cornell University -
- Adjunct Professor Lankenau Institute for Medical Research -
Awards
- ASCO Young Investigator Award Year
- Kristen Carr Fellowship Year
- Yale University Ohse Fellowship Year
- Royal College of Surgeons Trubshaw Medal Year
- University of Cambridge Churchill Fellowship Year
- Kristen Ann Carr Fellowship Year
- Sarcoma Foundation of America Hope and Vision Award Year
Professional Memberships
- ASCO, AACR
Fellowships
- Memorial Sloan-Kettering Cancer Center 1994
Professional Society Memberships
- FRCS, FACS, RSM, ASCO, AACR
What do you attribute your success to?
- Caring for his patients and their journey.
Jonathan Lewis, MD, PhD's Practice location
Jonathan Lewis, MD, PhD's reviews
Write ReviewMedia Releases
Where Precision Meets Impact: Pioneering Immunotherapies that Revolutionize Cancer Treatment
Dr. Jonathan Lewis has joined Syncromune as the Chief Strategy Officer, bringing his wealth of experience in cancer research and immunotherapies to lead the development of an innovative in situ platform therapy for metastatic solid tumor cancers. Syncromune, a clinical-stage biopharmaceutical company, aims to revolutionize cancer treatment with high response rates and potentially improved survival outcomes.
With a distinguished career in global translational and clinical research, Dr. Lewis has held key leadership positions at renowned biopharmaceutical companies. As the former Executive Chairman, CEO, and Chief Medical Officer of Ziopharm Oncology, he spearheaded the development of groundbreaking immunotherapies for metastatic cancers. Prior to that, he served as Chairman and Chief Medical Officer of Antigenics, Inc, focusing on personalized therapeutic vaccines for various diseases.
Dr. Lewis is a highly respected figure in the medical and scientific community, serving as Chairman of three boards and Director of two others. His educational background includes an M.D. from Witwatersrand University and a Ph.D. from Yale University, with additional training at esteemed institutions such as The Royal College of Surgeons in Edinburgh, Cambridge University, and Memorial Sloan-Kettering Cancer Center.
At Memorial Sloan-Kettering Cancer Center in New York, Dr. Lewis made significant contributions as an attending surgeon in the Department of Surgery and as an attending physician in the Clinical Immunology Service, Division of Hematologic Oncology. He also held a professorship at Weill Medical College of Cornell University, and currently serves as an Adjunct Professor at Lankenau Institute for Medical Research.
Recognized for his exceptional leadership and fundraising abilities, Dr. Lewis has raised over 1 billion US dollars in equity, nonprofit, and government funding. His achievements have been acknowledged with prestigious honors and awards in medicine and science, including the ASCO Young Investigator Award, the Kristen Carr Fellowship, the Yale University Ohse Fellowship, the Royal College of Surgeons Trubshaw Medal, the University of Cambridge Churchill Fellowship, the inaugural Kristen Ann Carr Fellowship, and the Sarcoma Foundation of America Hope and Vision Award. His extensive research has led to over 200 scientific publications and contributions to numerous textbooks in the field of cancer biology and treatment.
Syncromune is thrilled to welcome Dr. Jonathan Lewis to its team as Chief Strategy Officer, confident that his expertise and vision will drive the company towards developing innovative cancer therapies that have the potential to transform patient outcomes.
Recommended Articles
- How Your Father’s Genes Can Affect Your Ovarian Cancer Risk
It is well known that inherited mutations in BRCA1/BRCA2 genes increase the risk of breast and ovarian cancers, as well as other types of cancer. An altered mutation in the BRCA1 or BRCA2 gene can be inherited from an individual’s mother or father. ...
- New Advancement to Reduce Rate of Breast Cancer Spreading
One of the most difficult aspects of treating cancer is fighting against the speed at which the cancer spreads throughout the body. As cells grow and multiply, they begin to affect larger systems in the body, and can metastasize to different systems entirely. Once a cancer has spread from the...
- What Are the Early Signs of Lung Cancer?
Lung cancer allows a five-year survival limit, and that is if the disease has not spread elsewhere in the body. This is all the more reason to be alert to early warnings of cancer’s approach. With early detection, cancer survival ratings improve remarkably.1. Misery and mood swingsCarrying the...
- Is Hepatitis B Contagious?
The hepatitis virus is one of the liver’s greatest enemies. It causes infections that can severely malfunction the liver, resulting in various conditions like scarring of the liver, liver failure, or even liver cancer. The hepatitis viruses have three types, namely, A, B, and C. While all three...
- Is Hormone Replacement Therapy Preventing Women from Getting Mammograms?
According to a new study, the sudden drop in the rate of mammograms taken by women is due to the fear of hormone replacement therapy (HRT). Up to the year 2000, many women used to take up mammography, once every two years, as a screening method for breast cancer. By the year 2005, researchers...
- Is Ovarian Cancer Genetic?
What is Ovarian Cancer?Ovarian cancer is a very dangerous disease that occurs when malignant cells are found in the ovaries. It effects mostly women from 60-63 years old, but can happen to a woman of any age. Ovaries are a pair of organs that produce fertile hormones and eggs in women. Because...